PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Specht, H.M.* ; Ahrens, N.* ; Blankenstein, C.* ; Duell, T.H.G.* ; Fietkau, R.J.* ; Gaipl, U.S.* ; Günther, C.* ; Gunther, S.* ; Habl, G.* ; Hautmann, H.* ; Hautmann, M.G.* ; Huber, R.M.* ; Molls, M.M.* ; Offner, R.* ; Rödel, C.M.* ; Rödel, F.* ; Schuetz, M.* ; Combs, S.E.* ; Multhoff, G.

Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial.

Front. Immunol. 6:162 (2015)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Heat shock protein 70 (Hsp70) is frequently overexpressed in tumor cells. An unusual cell surface localization could be demonstrated on a large variety of solid tumors including lung, colorectal, breast, squamous cell carcinomas of the head and neck, prostate and pancreatic carcinomas, glioblastomas, sarcomas and hematological malignancies, but not on corresponding normal tissues. A membrane (m)Hsp70-positive phenotype can be determined either directly on single cell suspensions of tumor biopsies by flow cytometry using cmHsp70.1 monoclonal antibody or indirectly in the serum of patients using a novel lipHsp70 ELISA. A mHsp70-positive tumor phenotype has been associated with highly aggressive tumors, causing invasion and metastases and resistance to cell death. However, natural killer (NK), but not T cells were found to kill mHsp70-positive tumor cells after activation with a naturally occurring Hsp70 peptide (TKD) plus low dose IL-2 (TKD/IL-2). Safety and tolerability of ex vivo TKD/IL-2 stimulated, autologous NK cells has been demonstrated in patients with metastasized colorectal and NSCLC in a phase I clinical trial. Based on promising clinical results of the previous study, a phase II randomized clinical study was initiated in 2015. The primary objective of this multicenter proof-of-concept trial is to examine whether an adjuvant treatment of NSCLC patients after platinum based radiochemotherapy with TKD/IL-2 activated, autologous NK cells is clinically effective. As a mHsp70-positive tumor phenotype is associated with poor clinical outcome only mHsp70-positive tumor patients will be recruited into the trial. The primary endpoint of this study will be the comparison of the progression-free survival of patients treated with ex vivo activated NK cells compared to patients who were treated with radiochemotherapy alone. As secondary endpoints overall survival, toxicity, quality-of-life and biological responses will be determined in both study groups.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
0.000
1.042
72
70
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Hsp70-based Immunotherapy ; Nk Cells ; Nsclc Patients ; Clinical Phase Ii ; Radiochemotherapy Clinical Trial; Heat-shock Proteins; Membrane-bound Heat-shock-protein-70; Tumor-cells; Recognition Structure; Cytolytic Activity; Surface; Binding; Chemoradiation; Metastasis; Expression
Sprache englisch
Veröffentlichungsjahr 2015
HGF-Berichtsjahr 2015
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Zeitschrift Frontiers in Immunology
Quellenangaben Band: 6, Heft: , Seiten: , Artikelnummer: 162 Supplement: ,
Verlag Frontiers
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501390-001
PubMed ID 25926832
DOI 10.3389/fimmu.2015.00162
WOS ID WOS:000354934100001
Scopus ID 84934298607
Scopus ID 84926683486
Erfassungsdatum 2015-04-19
[➜Korrektur melden]